CagriSema (Cagrilintide + Semaglutide): A Research Guide

What is CagriSema?

CagriSema is a fixed-dose combination of two peptides: cagrilintide (2.4 mg), a long-acting amylin analogue, and semaglutide (2.4 mg), a GLP-1 receptor agonist. Developed by Novo Nordisk, it is the first drug to combine amylin and GLP-1 signaling in a single once-weekly subcutaneous injection.

The rationale is mechanistic complementarity. Semaglutide reduces appetite and slows gastric emptying through GLP-1 receptor activation — a pathway now well-established across three generations of GLP-1 drugs. Cagrilintide adds amylin receptor signaling, which enhances satiety through a distinct hypothalamic pathway, independently suppresses glucagon, and slows gastric emptying via a separate mechanism. The two signals converge on appetite regulation without competing for the same receptor, making the combination pharmacologically non-redundant.

This is not simply additive dosing. In head-to-head comparisons, CagriSema outperformed semaglutide monotherapy by 7–8 percentage points in weight reduction, a margin that represents genuine pharmacological synergy.

Mechanism of action

GLP-1 receptor agonism (semaglutide component). Semaglutide activates the GLP-1 receptor in the gut, pancreas, and hypothalamus. It increases insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and reduces appetite centrally by acting on the arcuate nucleus of the hypothalamus. The result is reduced caloric intake, improved glycemic control, and sustained weight loss. For a detailed breakdown of GLP-1 class pharmacology, see our GLP-1 vs Dual Agonist vs GLP-3 comparison article.

Amylin receptor agonism (cagrilintide component). Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells. It signals satiety through the area postrema and nucleus tractus solitarius — brain regions distinct from the primary GLP-1 signaling targets. Amylin independently suppresses post-meal glucagon, reduces gastric emptying rate, and promotes early satiety through a pathway that does not desensitize in parallel with GLP-1 receptors. Cagrilintide is a long-acting amylin analogue with a half-life of approximately one week, enabling once-weekly dosing synchronized with the semaglutide component.

Combined effect. By targeting both the GLP-1 pathway and the amylin pathway simultaneously, CagriSema achieves appetite suppression at two mechanistically independent sites. This dual-pathway approach is the pharmacological basis for the superior weight loss observed in the REDEFINE trials compared to semaglutide alone.

The REDEFINE Phase 3 trial program

REDEFINE 1 — Adults with overweight or obesity (no diabetes). Published in the New England Journal of Medicine. 3,417 participants at 68 weeks: CagriSema produced 22.7% mean weight loss (all-adherent estimand) vs. 16.1% for semaglutide alone, 11.8% for cagrilintide alone, and 3.0% for placebo. 40.4% of CagriSema participants achieved ≥25% weight loss. 88% of participants with prediabetes at baseline returned to normoglycemia.

REDEFINE 2 — Adults with type 2 diabetes. CagriSema produced 15.7% weight loss, superior to semaglutide monotherapy, with an HbA1c reduction of 1.91 percentage points.

REDEFINE 4 — Head-to-head vs. tirzepatide (open-label, 809 participants). Results announced February 2026: CagriSema achieved 23.0% weight loss (all-adherent estimand) vs. tirzepatide 15mg at 25.5%. CagriSema did not achieve non-inferiority to tirzepatide on the primary endpoint, with approximately a 2.5 percentage point gap — but both compounds delivered clinically meaningful weight loss. GI adverse events were mild-to-moderate and diminished at maintenance dose.

How CagriSema compares across the GLP-1 class

CagriSema occupies a distinct pharmacological niche from tirzepatide and retatrutide. While those compounds add GIP and glucagon receptor inputs, CagriSema pairs GLP-1 with the amylin satiety system — a mechanistically different approach to comparable outcomes.

Research dosing protocol

The following reflects the titration schedule used in the REDEFINE trial program. Research use only — not medical advice.

Administration: Once-weekly subcutaneous injection. Rotate injection sites (abdomen, thigh, upper arm).

Reconstitution: Reconstitute each component per vial size and supplier specification. Administer as two separate subcutaneous injections on the same day, or use a pre-blended vial if available. Titrate both compounds at the same rate — synchronized escalation is critical. Most GI side effects occur during dose escalation and diminish at maintenance. Do not combine with other GLP-1 agonists (retatrutide, tirzepatide, or other semaglutide products).

Regulatory status (May 2026)

Novo Nordisk filed the NDA with the FDA on December 18, 2025. The expected FDA decision window is October–December 2026. CagriSema is investigational — not yet FDA approved in any territory. A 7,000-participant cardiovascular outcomes trial (REDEFINE CV) is still underway.

Note: The FDA's April 30, 2026 proposal to remove semaglutide from the 503B compounding bulks list affects the availability of the compounded semaglutide component. See the companion article: FDA GLP-1 Compounding Update — May 2026.

Safety profile

Common adverse events across the REDEFINE program include nausea (most common, especially during titration — typically resolves at maintenance), vomiting, diarrhea, and constipation. Gallbladder events occurred at rates consistent with GLP-1 class compounds. No new safety signals were identified beyond expected GLP-1 and amylin class effects.

Precautions: Do not use in personal or family history of medullary thyroid carcinoma or MEN2. Monitor for pancreatitis. All precautions applicable to semaglutide apply to the semaglutide component of CagriSema.

Research references

• Lincoff AM, et al. (2025). Cagrilintide and Semaglutide in Obesity — NEJM (REDEFINE 1)
• Enebo LB, et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide — Lancet
• Novo Nordisk (February 2026). REDEFINE 4 results press release

Research sourcing: For research-grade GLP-1 class peptides with third-party COA documentation, Peptide Hub recommends Amino Club (partner code: PEPTIDEHUB). Affiliate link — we earn a commission at no cost to you.